Form 4: Anne McGeorge Acquires Stock Options in Dianthus Therapeutics

Director Anne McGeorge acquired stock options for 12,500 shares of Dianthus Therapeutics common stock on May 22, 2025.

Summary

• On May 22, 2025, Anne McGeorge, a director of Dianthus Therapeutics, Inc., acquired stock options to purchase 12,500 shares of the company's common stock.
• The exercise price of the stock options is $18.36 per share.
• The options vest on the earlier of the first anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service to the Issuer.
• The options expire on May 22, 2035.
• Following the transaction, Ms. McGeorge directly owns 12,500 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's increased stake in the company through stock options, aligning their interests with shareholders. It's a routine filing, but the acquisition itself suggests confidence.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continued service to the Issuer, aligning their interests with the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's investment in the company's future.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Stock Options, Dianthus Therapeutics, Form 4, Director, Beneficial Ownership, DNTH, McGeorge, Equity